MX2020007036A - Combinaciones de inhibidores ripk1 e ikk para la prevención o tratamiento de enfermedades inmunitarias. - Google Patents

Combinaciones de inhibidores ripk1 e ikk para la prevención o tratamiento de enfermedades inmunitarias.

Info

Publication number
MX2020007036A
MX2020007036A MX2020007036A MX2020007036A MX2020007036A MX 2020007036 A MX2020007036 A MX 2020007036A MX 2020007036 A MX2020007036 A MX 2020007036A MX 2020007036 A MX2020007036 A MX 2020007036A MX 2020007036 A MX2020007036 A MX 2020007036A
Authority
MX
Mexico
Prior art keywords
inhibitors
ripk1
combinations
treatment
prevention
Prior art date
Application number
MX2020007036A
Other languages
English (en)
Inventor
Manolis Pasparakis
Nikos Oikonomou
Apostolos Polykratis
Original Assignee
Univ Koeln
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Koeln filed Critical Univ Koeln
Publication of MX2020007036A publication Critical patent/MX2020007036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al tratamiento de enfermedades asociadas con una respuesta inmune desregulada, tales como trastornos autoinmunes, enfermedades inflamatorias o respuestas inmunes patológicas como efectos adversos de tratamientos médicos. En particular, la invención proporciona un uso combinado de inhibidores de la serina/treonina-proteína quinasa 1 que interactúan con el receptor (RIPK1) y los inhibidores de inhibidor de ?B (I?B) quinasa (IKK) en sujetos que padecen tales trastornos. La invención proporciona dichos compuestos inhibidores y sus combinaciones para su uso en aplicaciones médicas, así como composiciones farmacéuticas que comprenden los compuestos de la invención.
MX2020007036A 2017-12-07 2018-12-07 Combinaciones de inhibidores ripk1 e ikk para la prevención o tratamiento de enfermedades inmunitarias. MX2020007036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17205864.6A EP3494994A1 (en) 2017-12-07 2017-12-07 Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
PCT/EP2018/084055 WO2019110832A1 (en) 2017-12-07 2018-12-07 Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases

Publications (1)

Publication Number Publication Date
MX2020007036A true MX2020007036A (es) 2020-12-03

Family

ID=60629504

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007036A MX2020007036A (es) 2017-12-07 2018-12-07 Combinaciones de inhibidores ripk1 e ikk para la prevención o tratamiento de enfermedades inmunitarias.

Country Status (7)

Country Link
US (1) US12678447B2 (es)
EP (2) EP3494994A1 (es)
JP (1) JP7527639B2 (es)
CN (1) CN111670049A (es)
CA (1) CA3103847A1 (es)
MX (1) MX2020007036A (es)
WO (1) WO2019110832A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494994A1 (en) 2017-12-07 2019-06-12 Universität zu Köln Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
AU2020391425A1 (en) 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease
EP4209213A1 (en) * 2022-01-05 2023-07-12 Universität zu Köln Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases
WO2024170776A1 (en) 2023-02-17 2024-08-22 Universität Zu Köln Triple kinase inhibition for the treatment of type i interferon response associated disorders
CN119064582B (zh) * 2024-09-02 2025-05-27 南方医科大学南方医院 RIPK1 O-GlcNAc糖基化抑制剂在制备增强肾细胞癌舒尼替尼敏感性药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032287A3 (cs) * 2001-02-01 2004-02-18 Bristol-Myers Squibb Company Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)
EP2029608A1 (en) * 2006-06-06 2009-03-04 Boehringer Ingelheim International GmbH Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
ES2555160B1 (es) * 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
RU2017109122A (ru) * 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
EP3017825A1 (en) * 2014-11-06 2016-05-11 Ludwig-Maximilians-Universität München An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same
EP3494994A1 (en) 2017-12-07 2019-06-12 Universität zu Köln Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases

Also Published As

Publication number Publication date
EP3494994A1 (en) 2019-06-12
EP3720493B1 (en) 2024-07-24
WO2019110832A1 (en) 2019-06-13
JP7527639B2 (ja) 2024-08-05
US20200383995A1 (en) 2020-12-10
US12678447B2 (en) 2026-07-14
EP3720493A1 (en) 2020-10-14
JP2021505611A (ja) 2021-02-18
CA3103847A1 (en) 2019-06-13
CN111670049A (zh) 2020-09-15
EP3720493C0 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
ZA202502751B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
EP4234551A3 (en) Pyridazinones as parp7 inhibitors
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
MX2023009652A (es) Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras.
PH12016501107B1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
MX373658B (es) Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2-il)amino-benzoico como inhibidor de quinasa p38.
WO2016172134A3 (en) Novel compounds
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
MX2020006614A (es) Derivados de cromenopiridina como inhibidores de fosfatidilinositol fosfato cinasa,.
MX371153B (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX371152B (es) Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk).
MX371150B (es) NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
WO2015106200A3 (en) Dipeptides as inhibitors of human immunoproteasomes
EP3720493C0 (en) COMBINATIONS OF RIPK1 AND IKK INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
WO2016028571A3 (en) Dipeptidomimetics as inhibitors of human immunoproteasomes
PH12019500464A1 (en) An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy
EA201891687A1 (ru) Новые замещённые производные цианиндолина в качестве nik- ингибиторов
EA201990393A1 (ru) Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств
HK1248601A1 (zh) 作為激酶抑制劑的嘧啶衍生物及其治療應用